T1 Condition 470 477  RR-DTC
T2 Protein 272 283 subanalysis
T3 Organism 1795 1803 patients
T4 Biomarker 1267 1277 lenvatinib
T6 Organism 1870 1878 patients
T7 Organism 1286 1294 patients
T8 Organism 1516 1524 patients
T9 Biomarker 1583 1593 lenvatinib
T10 Protein 814 817 PFS
T11 Protein 1323 1326 ORR
T12 Protein 625 628 PFS
T13 Protein 127 143 progression-free
T14 Biomarker 546 556 lenvatinib
T15 Disease 1655 1663 toxicity
T16 Biomarker 846 856 lenvatinib
T17 Organism 1686 1694 patients
T18 Condition 74 81 Thyroid
T19 Biomarker 92 102 lenvatinib
T20 Intervention 744 748 arms
T21 Organism 177 185 patients
T23 Condition 1895 1901 RR-DTC
T24 Protein 1094 1097 PFS
T26 Organism 518 526 Patients
T27 Organism 1267 1294 lenvatinib-treated patients
T28 Protein 1540 1551 subanalysis
T29 Condition 245 251 RR-DTC
T30 Organism 356 364 Patients
T31 Biomarker 1821 1831 lenvatinib
T33 Biomarker 345 355 lenvatinib
T34 Biomarker 1172 1182 lenvatinib
T35 Protein 1574 1577 PFS
T36 Organism 432 440 patients
T37 Protein 921 924 PFS
T38 Organism 1172 1199 lenvatinib-treated patients
T39 Condition 191 244 radioiodine-refractory differentiated thyroid cancer 
T40 Condition 60 66 Cancer
